The Korean CDMO’s new viral vector platforms can significantly save the production time and cost of AAV and lentiviral vectors By Ji-Hyun Lee SK pharmteco Co., South Korean conglomerate SK Group’s contract development and manufacturing organization (CDMO), has recently introduced two new viral vector platforms that are expected to save the time and cost of […]
Designed to shorten turnaround on manufacturing AAVs, this new platform offers Cell and Gene Therapy developers more flexibility in producing viral vectors for clinical and commercial use Evry-Courcouronnes (near Paris), France, November 7, 2023 – Yposkesi, SK pharmteco’s European clinical and commercial viral vector manufacturing subsidiary for Cell and Gene Therapies (C>), today launches AAVelocityTM,
RANCHO CORDOVA, Calif. and KING OF PRUSSIA, Pa., Oct. 18, 2023 /PRNewswire/ — SK pharmteco will participate at the CPHI 2023 in Barcelona and prepare a dedicated booth at the event. As a multi-modality CDMO with expertise in small molecule active pharmaceutical ingredients (APIs) and biopharmaceuticals, SK pharmteco aims to present its business competitiveness and actively pursue business opportunities. With a dedicated booth
SK pharmteco to Showcase its Extensive APIs and CGT Capabilities at CPHI 2023 Read More »
On Sept. 15, 2023, CPHI Barcelona announced the finalists for the 2023 CPHI Pharma Awards. The awards ceremony will be held on Oct. 24, 2023, the opening day of CPHI Barcelona, the world’s largest pharma event, at the Fiera Barcelona. SK pharmteco (SKPT) was honored to be among 12 finalists in the “Accelerating Innovation” category.
SK pharmteco is a Pharma Award Finalist for CPHI Barcelona 2023 Read More »
SK Inc. to invest $350M through SK pharmteco. SK Inc. announced on January 9th that it has invested $350 million in the Center for Breakthrough Medicines (CBM), a Pennsylvania-based CGT CDMO, to become the second-largest shareholder…
SK Inc. to invest $350M through SK pharmteco Read More »
"*" indicates required fields
